WASHINGTON, D.C. – The Advanced Medical Technology Association (AdvaMed) today named DeChane Dorsey the new Executive Director of AdvaMed Accel, the division within AdvaMed dedicated to the needs of small and start-up medical technology manufacturers. DeChane was previously AdvaMed’s Vice President of Payment and Health Care Delivery Policy, a role she has held since 2006.
Scott Whitaker, President and CEO of AdvaMed, commented on DeChane’s new appointment, saying:
“DeChane is an exceptional and intelligent leader. She is thorough and thoughtful; she conducts herself with grace and grit; she provides valued counsel and is a great confidant. It’s her innovative spirit and can-do attitude that make DeChane the right choice to lead AdvaMed Accel at this important time in our history.
Numed, a well established company in business since 1975 provides a wide range of service options including time & material service, PM only contracts, full service contracts, labor only contracts & system relocation. Call 800 96 Numed for more info.
“DeChane has helped secure many policy wins in the coding and reimbursement landscape – on the physician fee schedule, hospital outpatient prospective payment system, and ambulatory surgery center payment system.
“But her work extends beyond the payment space. During a challenging year marked by racial unrest, DeChane led AdvaMed’s health equity work, which has been a tremendous accomplishment for our industry. Her leadership helped solidify AdvaMed as a solution-oriented thought leader in the health equity discussion.
“I know our small medtech companies – the lifeblood of the medtech industry – will flourish with her at the helm.”
Martha Shadan, President and CEO of Miach Orthopaedics and Chair of AdvaMed Accel, echoed Whitaker’s sentiments, saying:
“AdvaMed Accel operates on one founding principle: Small medical technology manufacturers have unique needs that require specialized attention within the AdvaMed network. These issues have never been more apparent – and that specialized attention has never been more important – than right now during the Covid-19 pandemic. We’re so pleased to have someone of DeChane’s caliber take leadership of Accel at this critical time.
She has the know-how and the experience our organization needs to be successful, but more than that, she has the passion and the dedication it takes to ensure that our success is sustained and significant.
I can’t wait to start working with DeChane, so, together, we can make sure today’s emerging medtech companies are able to deliver tomorrow’s medical miracles.”
DeChane confirmed her excitement and readiness to take on the top role at AdvaMed Accel, saying:
“Our AdvaMed Accel members are on the verge of some of the most promising medical breakthroughs – and they depend on AdvaMed Accel to help them take their ideas from inception to market.